Abstract:Despite a strong preclinical rationale for targeting the insulin-like growth factor (IGF) axis in cancer, clinical studies of IGF-1 receptor (IGF-1R)-targeted monotherapies have been largely disappointing, and any potential success has been limited by the lack of validated predictive biomarkers for patient enrichment. A large body of preclinical evidence suggests that the key role of the IGF axis in cancer is in driving treatment resistance, via general proliferative/survival mechanisms, interactions with other mitogenic signaling networks, and class-specific mechanisms such as DNA damage repair. Consequently, combining IGF-targeted agents with standard cytotoxic agents, other targeted agents, endocrine therapies, or immunotherapies represents an attractive therapeutic approach. Anti-IGF-1R monoclonal antibodies (mAbs) do not inhibit IGF ligand 2 (IGF-2) activation of the insulin receptor isoform-A (INSR-A), which may limit their anti-proliferative activity. In addition, due to their lack of specificity, IGF-1R tyrosine kinase inhibitors are associated with hyperglycemia as a result of interference with signaling through the classical metabolic INSR-B isoform; this may preclude their use at clinically effective doses. Conversely, IGF-1/IGF-2 ligand-neutralizing mAbs inhibit proliferative/anti-apoptotic signaling via IGF-1R and INSR-A, without compromising the metabolic function of INSR-B. Therefore, combination regimens that include these agents may be more efficacious and tolerable versus IGF-1R-targeted combinations. Herein, we review the preclinical and clinical experience with IGF-targeted therapies to-date, and discuss the rationale for future combination approaches as a means to overcome treatment resistance.

Cell cycle control by the insulin-like growth factor signal: at the crossroad between cell growth and mitotic regulation

Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival

Advances in Targeting Insulin-Like Growth Factor Signaling Pathway in Cancer Treatment.

Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy

Cellular signals integrate cell cycle and metabolic control in cancer

Impact on Cancer Hallmarks and Therapeutic Approaches

Role of Insulin-Like Growth Factor-1 (IGF-1) in Regulating Cell Cycle Progression

Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer.

Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors in cancer therapy: advances and perspectives.

Regulation of Cell Cycle Progression by Growth Factor-Induced Cell Signaling

Insulin-like Growth Factor-1 Promotes Cell Cycle Progression Via Upregulation of Cyclin D1 Expression Through the Phosphatidylinositol 3-Kinase/nuclear Factor-Κb Signaling Pathway in FRTL Thyroid Cells

Human IGF2 Gene Epigenetic and Transcriptional Regulation: At the Core of Developmental Growth and Tumorigenic Behavior

Cyclins and cdks in development and cancer: a perspective

Cell cycle regulation and anticancer drug discovery

IGF2: A Role in Metastasis and Tumor Evasion from Immune Surveillance?

Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies

[Progress in the Studies on Small Molecule IGF-1R Inhibitors].

Circadian patterns of growth factor receptor-dependent signaling and implications for carcinogenesis

Ubiquitin signaling in cell cycle control and tumorigenesis

Decoding the Role of Insulin-like Growth Factor 1 and Its Isoforms in Breast Cancer

Insulin-Like Growth Factor and Epidermal Growth Factor Signaling in Breast Cancer Cell Growth: Focus on Endocrine Resistant Disease